Analysis of the pre-selected signatures in the HER2+ cohort showed similar results to those observed in the HER2− tumours (Additional file 7: Figure S5b, Additional file 10: Figure S7b, Additional file 11: Figure S8b; Additional file 8: Table S18B, S19B, S20B). The gene discussed is ERBB2; the disease is neoplasm.